{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:24:14Z","timestamp":1749623054559,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2019]]},"abstract":"<b><i>Aim:<\/i><\/b> Bleomycin is an antitumor antibiotic used successfully to treat a variety of malignancies, predominantly germ cell tumors and Hodgkin\u2019s lymphoma (HL). The major limitation of bleomycin therapy is the potential for life-threatening interstitial pulmonary fibrosis. Early identification of asymptomatic patients who may develop toxicity is important. We aimed to evaluate fluorodeoxyglucose positron-emission tomography (FDG-PET\/CT) findings to predict bleomycin toxicity (BT) early after chemotherapy with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy before clinical symptoms and radiological changes occur. <b><i>Materials and Methods:<\/i><\/b> HL patients who were treated with ABVD were evaluated. SUVmax values of lung parenchyma were analyzed in FDG-PET\/CT at diagnosis and after 4 cycles of chemotherapy in all patients. At the end of the chemotherapy cycles, lung parenchymal SUVmax values of patients with BT and without BT were compared statistically. <b><i>Results:<\/i><\/b> Twenty (66.7%) male and 10 (33.3%) female patients with HL were included. Five (16.7%) HL patients developed BT. In 3 HL patients, BT was determined after 5 cycles and in 2 patients, BT was seen after 6 cycles. In all 5 of these patients with BT, FDG uptake in PET-CT was increased after 4 cycles of chemotherapy and BT was predicted before clinical and radiological findings by FDG-PET\/CT. After 4 cycles of chemotherapy, lung parenchymal SUVmax of patients with BT (3.24 \u00b1 0.76) was significantly higher than in patients without toxicity (1.84 \u00b1 0.52) (<i>p<\/i> &#x3c; 0.001). In patients with BT, a significant increase was established in lung parenchymal SUVmax after 4 cycles of chemotherapy when compared to the time of diagnosis (<i>p<\/i> = 0.043). <b><i>Conclusion:<\/i><\/b> BT can be fatal. Early detection of BT is essential in clinical practice. FDG-PET\/CT can predict BT before clinical and radiological findings occur.<\/jats:p>","DOI":"10.1159\/000502374","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T21:00:34Z","timestamp":1566939634000},"page":"171-175","source":"Crossref","is-referenced-by-count":7,"title":["Can We Predict Bleomycin Toxicity with PET-CT?"],"prefix":"10.1159","volume":"142","author":[{"given":"Seda","family":"Beyhan\u00a0Sagmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevda","family":"Comert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Turan\u00a0Erkek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysun","family":"K\u00fc\u00e7\u00fck\u00f6z\u00a0Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Co\u015fkun","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guven","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrin","family":"K\u0131ral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fla","family":"Y\u0131lmaz\u00a0Haksal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Torun\u00a0Parmaks\u0131z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.2.617"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2008::AID-CNCR18>3.0.CO;2-M"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg020"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-008-0183-7"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000101517"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11856"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-007-0089-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0031OC"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00176.2011"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034905"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.779"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1236379"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-015-0388-3"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/502374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/502374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:51:06Z","timestamp":1745423466000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000502374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,17]]},"published-print":{"date-parts":[[2019,9,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000502374","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"type":"print","value":"0001-5792"},{"type":"electronic","value":"1421-9662"}],"subject":[],"published":{"date-parts":[[2019]]}}}